Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy? (Q28269068)

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

4 January 2025

3

Paul Mitchell

0 references

Tien Y Wong

1

object named as

Tien Yin Wong

1 reference

Europe PubMed Central

PubMed publication ID

22709833

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22709833

4 January 2025

author name string

Rafael Simó

2

1 reference

Europe PubMed Central

PubMed publication ID

22709833

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22709833

full work available at URL

4 January 2025

language of work or name

English

0 references

publication date

July 2012

0 references

https://api.elsevier.com/content/article/PII:S0002939412002048?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

https://api.elsevier.com/content/article/PII:S0002939412002048?httpAccept=text/plain

4 January 2025

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

American Journal of Ophthalmology

4 January 2025

published in

0 references

volume

154

0 references

issue

1

0 references

page(s)

6-12

0 references

cites work

Diabetic retinopathy

1

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Diabetic retinopathy in a multi-ethnic cohort in the United States

4 January 2025

2

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

The economic burden of major adult visual disorders in the United States

4 January 2025

3

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the diabetes care system west-friesland, the Netherlands

4 January 2025

4

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis

4 January 2025

5

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Management of diabetic retinopathy: a systematic review

4 January 2025

6

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

4 January 2025

7

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Advances in the medical treatment of diabetic retinopathy

4 January 2025

8

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Emerging Evidence Concerning Systemic Safety of Anti-VEGF Agents – Should Ophthalmologists Be Concerned?

4 January 2025

9

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

4 January 2025

10

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Effect of a multifactorial intervention on mortality in type 2 diabetes

4 January 2025

11

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Effects of medical therapies on retinopathy progression in type 2 diabetes

4 January 2025

12

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Effects of intensive glucose lowering in type 2 diabetes

4 January 2025

13

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

4 January 2025

14

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

4 January 2025

15

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Lipids and diabetic retinopathy

4 January 2025

16

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Renal and retinal effects of enalapril and losartan in type 1 diabetes

4 January 2025

17

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

4 January 2025

18

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

4 January 2025

19

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

4 January 2025

20

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

4 January 2025

21

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Effects of combination lipid therapy in type 2 diabetes mellitus

4 January 2025

22

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

4 January 2025

23

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Possible differences between fibrates in pharmacokinetic interactions with statins

4 January 2025

24

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

4 January 2025

25

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

4 January 2025

26

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Fenofibrate: treatment of hyperlipidemia and beyond

4 January 2025

27

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Dyslipidaemia and microvascular disease in the retina

4 January 2025

28

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Mechanism of action of fibrates on lipid and lipoprotein metabolism

4 January 2025

29

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids

4 January 2025

30

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Novel versus traditional risk markers for diabetic retinopathy

4 January 2025

31

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Fenofibrate for diabetic retinopathy

4 January 2025

32

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy

4 January 2025

33

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Apolipoprotein A1 is overexpressed in the retina of diabetic patients.

4 January 2025

34

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner

4 January 2025

35

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway

4 January 2025

36

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions.

4 January 2025

37

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Fenofibrate and diabetic retinopathy

4 January 2025

38

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases

4 January 2025

39

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.

4 January 2025

40

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Fenofibric Acid Reduces Fibronectin and Collagen Type IV Overexpression in Human Retinal Pigment Epithelial Cells Grown in Conditions Mimicking the Diabetic Milieu: Functional Implications in Retinal Permeability

4 January 2025

41

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation

4 January 2025

42

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Fenofibrate inhibits angiogenesis in vitro and in vivo

4 January 2025

43

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Fibrate Use in the United States and Canada

4 January 2025

44

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Cost savings associated with detection and treatment of diabetic eye disease

4 January 2025

45

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis

4 January 2025

46

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden

4 January 2025

47

1 reference

https://api.crossref.org/works/10.1016/J.AJO.2012.03.013

4 January 2025

Identifiers

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22709833

1 reference

Consolidated OpenCitations Corpus – April 2017